Diadema Partners LP Acquires New Stake in Evolus, Inc. (NASDAQ:EOLS)

Diadema Partners LP acquired a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 97,423 shares of the company's stock, valued at approximately $1,076,000. Diadema Partners LP owned 0.15% of Evolus at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. KBC Group NV acquired a new position in Evolus during the 4th quarter worth $49,000. IFP Advisors Inc boosted its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Evolus during the fourth quarter worth about $106,000. Quantbot Technologies LP purchased a new stake in shares of Evolus during the fourth quarter worth approximately $118,000. Finally, Tradition Wealth Management LLC raised its holdings in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after acquiring an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Stock Performance

EOLS traded up $0.10 on Friday, reaching $11.65. The company had a trading volume of 800,262 shares, compared to its average volume of 668,009. The stock has a 50-day moving average price of $12.25 and a 200-day moving average price of $12.95. The stock has a market capitalization of $740.79 million, a PE ratio of -12.80 and a beta of 0.97. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Barclays boosted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Finally, BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.75.

Insider Activity

In other Evolus news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the transaction, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares of the company's stock, valued at $1,268,597.46. The trade was a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 60,575 shares of company stock valued at $794,369. Insiders own 6.10% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.